Revenue grew 52% year-over-year to $132M, driven by strong transplant and specialty oncology testing. Guidance was raised for 2026, with revenue expected to reach $490–$500M and adjusted EBITDA margin at 15%. Integration of NavDx and favorable Medicare policy support future growth.Based on CareDx…
Revenue grew 52% year-over-year to $132M, driven by strong transplant and specialty oncology testing. Guidance was raised for 2026, with revenue expected to reach $490–$500M and adjusted EBITDA margin at 15%. Integration of NavDx and favorable Medicare policy support future growth.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
